Shares of Laurus Labs moved higher by 9 per cent to Rs 504.50, bouncing 16 per cent from their intra-day low on the BSE in Friday’s trade on the back of heavy volumes on a positive outlook.
At 02:43 pm, the stock was trading 8 per cent higher at Rs 501, after hitting a low of Rs 433 earlier in the day. The trading volumes on the counter jumped over two-fold with a combined 9.9 million equity shares having changed hands on the NSE and BSE. In comparison, the S&P BSE Sensex was up 0.17 per cent at 57,375 points.
The stock slipped 7 per cent in opening trade after the company's revenues fell 20 per cent year-on-year to Rs 1,029 crore in the December quarter (Q3FY22) due to an impact of continued stocking concern in anti-retroviral (ARV) business. Profit after tax was down 43.7 per cent YoY at Rs 153.70 crore.
The company said its Q3FY22 results were impacted by lower sales of ARV, active pharmaceutical ingredients (APIs) and formulations due to stocking at channel partners and it expects improvement from January-March quarter (Q4).
“Increase demand for ARV business witnessing commodity customers and formation sales from global multilateral agencies come from Q4 onwards. And we believe that the sluggishness is only transitory in nature and should be normal from – onwards,” Laurus Labs said in a conference call.
The company added that despite a tough environment, it has demonstrated healthy gross margin expansion due to a better mix. Its earnings before interest tax and depreciation and amortization (EBITDA ) declined by 33 per cent to Rs 290 crore while EBITDA margins declined 535 bps to 27.7 per cent from last year mainly due to higher employee and other expenditure.
According to analysts, overall outlook remains positive with gradual improvement in demand and planned capacity expansions in portfolio based on complexity and scale.
"Results were a miss on all fronts for this quarter as drag in ARV business is sharper than expected and appears to have bottomed. In API, ARV specific impact should ease from Q4 with visible signs of demand stabilization while good traction for Other and Oncology API should help in gradual recovery. Steady market share gain in existing portfolio along with portfolio expansion remains key for recovery in Formulations. CRAMS business is on track to leverage new opportunities and extend services," said ICICI Securities in a note.
Despite today’s sharp up move, Laurus has underperformed the market by falling 20 per cent in the past six months, as against a 9 per cent rise in the S&P BSE Sensex. The stock had hit a record high of Rs 724 on August 12, 2021.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU